Group 1 - Shandong Province's Industrial and Information Technology Department has announced the proposed list of the ninth batch of manufacturing single champion enterprises, with two companies from Linyi City successfully selected [1] - Linyi's Luoxin Pharmaceutical Group and Linyi Lixin Aluminum Industry have been recognized, contributing to the region's manufacturing sector's high-end, intelligent, and green development [1] - Luoxin Pharmaceutical, a top 100 pharmaceutical company in China, focuses on digestive system diseases and has developed innovative drugs, including the national Class I innovative drug Tegoprazan, which is included in the 2025 National Medical Insurance Directory [1] Group 2 - Linyi Lixin Aluminum Industry is transforming the aluminum industry with a "short-process green industrial chain," achieving over 90% recycling rate of aluminum resources through its innovative model [2] - The company plans to expand its production capacity to 300,000 tons per year by 2026, with an expected annual sales revenue of 2.5 billion yuan [2] - Lixin Aluminum holds 14 national invention patents and 42 utility model patents, and has established five provincial and municipal R&D platforms, collaborating with universities to achieve internationally advanced technology levels [2] Group 3 - The Linyi district will enhance the cultivation mechanism for manufacturing single champion enterprises by providing targeted policy guidance and financial support [2] - The district aims to encourage technological breakthroughs and promote the transformation of scientific achievements [2] - A collaborative industrial community will be built, integrating leading enterprises with small and medium-sized suppliers [2]

12月17日，罗欣药业（维权）大宗交易成交385.73万股，成交额1859.19万元，占当日总成交额的25.55%，成交价4.82元，较 市场收盘价4.91元折价1.83%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-12-17 | 002793 | 罗欣药业 | 4.82 | 385.73 | 1,859.19中信证券股份有限 | 东方财富证券股份 | | | | | | | 公司北京总部证券 | 有限公司上海分公 | | | | | | | 营业部 | 글 | ...

Group 1 - The core point of the article is that Luoxin Pharmaceutical (002793) reported a total of 39,227 shareholders as of December 10, 2025 [1]

Core Viewpoint - The announcement of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, highlights the inclusion of several new drugs from various pharmaceutical companies, indicating potential growth opportunities in the healthcare sector [1][5]. Group 1: New Drug Inclusions - Green Leaf Pharmaceutical has five new products included in the 2025 National Medical Insurance Drug Catalog or the Commercial Health Insurance Innovative Drug Catalog, including MiMeiXin and RuiBaiLai, marking significant advancements in pain management and treatment options [2][6]. - RoXin Pharmaceutical's core innovative drug, TaiXinZan, has been included in the 2025 National Medical Insurance Drug Catalog, achieving full coverage for its approved indications [6][7]. - Dongcheng Pharmaceutical's product, Technetium-99m labeled Tetrakis, has been successfully included in the National Medical Insurance Drug Catalog, filling a gap in the market for myocardial perfusion imaging agents [8][9]. Group 2: Stock Performance - As of December 8, Green Leaf Pharmaceutical's stock price reached 3.05 yuan, reflecting a 40.55% increase since the beginning of the year [2][6]. - RoXin Pharmaceutical's stock price was 5.18 yuan as of December 9, showing a 35.6% increase year-to-date [7][8]. - Dongcheng Pharmaceutical's stock price was 14.66 yuan as of December 9, with a year-to-date increase of 20.26% [8][9]. - Rongchang Bio's stock price reached 85.29 yuan as of December 9, marking a significant increase of 183.25% since the start of the year [9]. Group 3: Innovative Treatments - MiMeiXin is noted as the first oral naloxone formulation in China for pain management, while RuiBaiLai offers a unique long-acting injection regimen [2][6]. - TaiXinZan has demonstrated superior efficacy in eradicating Helicobacter pylori compared to traditional treatments, showcasing its innovative therapeutic mechanism [7]. - HaiPuYi, a product from LuNan Pharmaceutical, has been included in the first edition of the Commercial Health Insurance Innovative Drug Catalog, addressing a critical shortage in the treatment of phenylketonuria [9].

Group 1 - The core point of the announcement is the completion of the capital increase and shareholding structure change of the controlling shareholder, Shandong Luoxin Holdings Co., Ltd., which increased its registered capital from 200 million RMB to 252 million RMB through an investment of 130 million RMB by the Linyi Luozhuang District New and Old Kinetic Energy Conversion Fund Investment Co., Ltd. [2][3] - The capital increase will not affect the number of shares or the shareholding ratio held by the controlling shareholder, nor will it change the company's governance structure or management team [2][3] - The business scope of Luoxin Holdings includes investment management and consulting, excluding financial, securities, futures, insurance, guarantee, and financing businesses [3] Group 2 - The company has implemented an employee stock ownership plan (ESOP) for 2024, which involves repurchasing shares to allocate to employees [5][6] - The total amount for the share repurchase is between 50 million RMB and 100 million RMB, with a maximum repurchase price of 7.62 RMB per share [5] - As of February 8, 2024, the company has repurchased 26,027,861 shares, accounting for 2.39% of the total share capital, with a total transaction amount of approximately 99.99 million RMB [5][6] - The ESOP allows for a maximum of 26,027,861 shares, with 18,219,503 shares granted initially at a price of 2.03 RMB per share, and a reserved portion of 7,808,358 shares at a price of 2.63 RMB per share [6][10] - The ESOP is structured to ensure that no single employee can hold more than 1% of the total share capital through the plan [11]

罗欣药业集团股份有限公司 关于控股股东新增注册资本暨股权结构变动的进展公告 证券代码：002793 股票简称：罗欣药业 公告编号：2025-107 8、经营范围：投资管理；投资咨询（以上经营项目均不含金融、证券、期 1 1、公司名称：山东罗欣控股有限公司 2、统一社会信用代码：91371300099660374D 3、类 型：其他有限责任公司 4、注册资本：25,200 万元人民币 5、成立日期：2014 年 05 月 14 日 6、住 所：山东省临沂市罗庄区湖东二路 77 号 货、保险、担保、融资业务）。（依法须经批准的项目，经相关部门批准后方可 开展经营活动） 三、备查文件 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次控股股东增资暨股权结构变动情况概述 2025 年 7 月 16 日，罗欣药业集团股份有限公司（以下简称"公司"）控股 股东山东罗欣控股有限公司（以下简称"罗欣控股"）通过股东会决议，同意临 沂市罗庄区新旧动能转换基金投资有限公司（以下简称"新旧动能基金"）对罗 欣控股增资 13,000 万元，认购新增注册资本 5,200 万元，股 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-108 罗欣药业集团股份有限公司 关于 2024 年员工持股计划预留份额部分股份 非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司于 2024 年 2 月 1 日召开第五届董事会第九次会议，审议通过了《关于 回购股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司部 分 A 股社会公众股份，用于员工持股计划或者股权激励。本次回购资金总额不 低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含），回购价格不超 过人民币 7.62 元/股（含），回购期限自董事会审议通过回购方案之日起 12 个月 内。截至 2024 年 2 月 8 日，本次回购股份方案实施完毕，公司通过股份回购专 用账户以集中竞价交易方式已累计回购公司股份 26,027,861 股，占公司总股本 2.39%，其中，回购的最高成交价为 4.21 元/股，最低成交价为 3.52 元/股，成交 总金额 99,986,148.24 元（不含交易费用）。 1 根据公司《2024 年员工持 ...

Group 1 - The core point of the article is that Luoxin Pharmaceutical announced an increase in capital by 130 million yuan from its controlling shareholder, Luoxin Holdings, which will raise its registered capital from 200 million yuan to 252 million yuan [1] - The new registered capital will consist of 52 million yuan, while four shareholders, including Liu Baoqi, have waived their subscription rights [1] - The capital increase has been officially registered, and Luoxin Holdings has obtained a new business license following the completion of the industrial and commercial change registration [1]

Group 1 - The core point of the article is that Luoxin Pharmaceutical (002793) reported a total of 39,154 shareholders as of November 28, 2025 [1]

Group 1 - The core point of the article is that Luoxin Pharmaceutical (SZ 002793) announced a board meeting to discuss the adjustment of the employee stock ownership plan for 2024, indicating ongoing corporate governance and strategic planning efforts [1] - For the first half of 2025, Luoxin Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 88.11%, pharmaceutical commerce for 10.1%, and other businesses for 1.79%, highlighting the company's strong focus on its core pharmaceutical manufacturing segment [1] - As of the report, Luoxin Pharmaceutical has a market capitalization of 5.9 billion yuan, reflecting its position in the market [1]